The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Bacterial Outer Membrane Vesicles and Vaccine Applications
Open accessAbstract
Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW), and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM), and BCG (dOMVBCG). The immunogenicity of the OMV has been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice has shown their protective potential. dOMVB has been evaluated with non-neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin, and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis
Brennan, P. J. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00089-6 · Cited by 884
Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R., & Terry, M. H. (1991) · PubMed · Cited by 512
Epidemic Pertussis in 2012 — The Resurgence of a Vaccine-Preventable Disease
Cherry, J. D. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1209051 · Cited by 472
Holst, J., Martin, D., Arnold, R., Huergo, C. C., Oster, P., O’Hallahan, J., & Rosenqvist, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.071 · Cited by 405
Self-citationAgger, E. M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B. S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., Christensen, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003116 · Cited by 287
OSTER, P., LENNON, D., OHALLAHAN, J., MULHOLLAND, K., REID, S., & MARTIN, D. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.063 · Cited by 271
Rosenqvist, E., Høiby, E. A., Wedege, E., Bryn, K., Kolberg, J., Klem, A., Rønnild, E., Bjune, G., & Nøkleby, H. (1995) · Infection and Immunity · doi:10.1128/iai.63.12.4642-4652.1995 · Cited by 249
Self-citationIncreased NOD2-mediated recognition of N-glycolyl muramyl dipeptide
Coulombe, F., Divangahi, M., Veyrier, F., de Léséleuc, L., Gleason, J. L., Yang, Y., Kelliher, M. A., Pandey, A. K., Sassetti, C. M., Reed, M. B., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081779 · Cited by 231
Holst, J., Oster, P., Arnold, R., Tatley, M., Næss, L., Aaberge, I., Galloway, Y., McNicholas, A., O'Hallahan, J., Rosenqvist, E., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24129 · Cited by 225
Self-citationStephens, D. S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.070 · Cited by 198
Witt, M. A., Arias, L., Katz, P. H., Truong, E. T., & Witt, D. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit046 · Cited by 192
van de Waterbeemd, B., Streefland, M., van der Ley, P., Zomer, B., van Dijken, H., Martens, D., Wijffels, R., & van der Pol, L. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.082 · Cited by 185
Immunization with Vibrio cholerae Outer Membrane Vesicles Induces Protective Immunity in Mice
Schild, S., Nelson, E. J., & Camilli, A. (2008) · Infection and Immunity · doi:10.1128/iai.00532-08 · Cited by 179
RUTI: A new chance to shorten the treatment of latent tuberculosis infection
Cardona, P.-J. (2006) · Tuberculosis · doi:10.1016/j.tube.2006.01.024 · Cited by 159
Asensio, C. J. A., Gaillard, M. E., Moreno, G., Bottero, D., Zurita, E., Rumbo, M., van der Ley, P., van der Ark, A., & Hozbor, D. F. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.068 · Cited by 129
Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine
Xie, O., Pollard, A. J., Mueller, J. E., & Norheim, G. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.036 · Cited by 126
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
Bai, X., Findlow, J., & Borrow, R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.585965 · Cited by 123
Liposome-based cationic adjuvant formulations (CAF): Past, present, and future
Christensen, D., Agger, E. M., Andreasen, L. V., Kirby, D. J., Andersen, P. L., & Perrie, Y. (2009) · Journal of Liposome Research · doi:10.1080/08982100902726820 · Cited by 120
Proteosome-Lipopeptide Vaccines: Enhancement of Immunogenicity for Malaria CS Peptides
Lowell, G. H., Ballou, W. R., Smith, L. F., et al. (1988) · Science · doi:10.1126/science.2452484 · Cited by 114
Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand
Arnold, R., Galloway, Y., McNicholas, A., & O’Hallahan, J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.120 · Cited by 113
Fries, L. F., Montemarano, A. D., Mallett, C. P., Taylor, D. N., Hale, T. L., & Lowell, G. H. (2001) · Infection and Immunity · doi:10.1128/iai.69.7.4545-4553.2001 · Cited by 110
Mycobacterium tuberculosis arabinomannan–protein conjugates protect against tuberculosis
Hamasur, B., Haile, M., Pawlowski, A., Schröder, U., Williams, A., Hatch, G. J., Hall, G. A., Marsh, P. D., Källenius, G., & Svenson, S. B. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00274-3 · Cited by 102
Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice
Camacho, A. I., de Souza, J., Sánchez-Gómez, S., Pardo-Ros, M., Irache, J. M., & Gamazo, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.121 · Cited by 95
Williams, J. N., Skipp, P. J. S., Humphries, H. E., Christodoulides, M., O’Connor, C. D., & Heckels, J. E. (2006) · Infection and Immunity · doi:10.1128/iai.01424-06 · Cited by 75
van der Ley, P., & van den Dobbelsteen, G. (2011) · Human Vaccines · doi:10.4161/hv.7.8.16086 · Cited by 75
Meningococcal protein antigens and vaccines
Feavers, I. M., & Pizza, M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.001 · Cited by 74
del Campo, J. M., Lindqvist, M., Cuello, M., Bäckström, M., Cabrerra, O., Persson, J., Pérez, O., & Harandi, A. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.035 · Cited by 55
Protollin™: a novel adjuvant for intranasal vaccines
Jones, T., Cyr, S. L., Allard, F., Bellerose, N., Lowell, G. H., & Burt, D. S. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.035 · Cited by 52
Mesa, C., de León, J., & Fernandez, L. E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.111 · Cited by 45
Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience
Miller, J. M., Mesaros, N. E., der Wielen, M. V., & Baine, Y. (2011) · Advances in Preventive Medicine · doi:10.4061/2011/846756 · Cited by 34
Rodriguez, L., Tirado, Y., Reyes, F., Puig, A., Kadir, R., Borrero, R., Fernandez, S., Reyes, G., Álvarez, N., Garcia, M. A., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.077 · Cited by 33
Self-citationProteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations
Burt, D. S., Mallett, C. P., Plante, M., Zimmermann, J., Torossian, K., & Fries, L. F. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.172 · Cited by 21
Mesa, C., de León, J., Rigley, K. P., & Fernandez, L. E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.114 · Cited by 18
Acevedo, R., Callicó, A., Aranguren, Y., Zayas, C., Valdés, Y., Pérez, Ó., García, L. G., Ferro, V. A., & Pérez, J. L. (2013) · BMC Immunology · doi:10.1186/1471-2172-14-s1-s10 · Cited by 17
Self-citationReyes, F., Tirado, Y., Puig, A., Borrero, R., Reyes, G., Fernández-Castillo, S., Pérez, J. L., Kadir, R., Zayas, C., Norazmi, M. N., et al. (2013) · BMC Immunology · doi:10.1186/1471-2172-14-s1-s7 · Cited by 16
Self-citation
Cited by
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
Brown, L., Wolf, J. M., Prados-Rosales, R., & Casadevall, A. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3480 · Cited by 1,324
The roles of extracellular vesicles in the immune system
Buzas, E. I. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00763-8 · Cited by 1,220
Exosomes and other extracellular vesicles in host–pathogen interactions
Schorey, J. S., Cheng, Y., Singh, P. P., & Smith, V. L. (2015) · EMBO reports · doi:10.15252/embr.201439363 · Cited by 727
Bacterial Outer Membrane Vesicles Mediate Cytosolic Localization of LPS and Caspase-11 Activation
Vanaja, S. K., Russo, A. J., Behl, B., Banerjee, I., Yankova, M., Deshmukh, S. D., & Rathinam, V. A. K. (2016) · Cell · doi:10.1016/j.cell.2016.04.015 · Cited by 727
Metadata
- Authors
- Acevedo, R., Fernández, S., Zayas, C., Acosta, A., Sarmiento, M. E., Ferro, V. A., Rosenqvist, E., Campa, C., Cardoso, D., Garcia, L., & Perez, J. L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2014-03-24
- Volume
- 5
- Pages
- 121-121
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W1992007086
- Cited by
- 254
- References
- 35
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.